Just as certain types of leukaemia hijack DOT1L to open up novel gene expression programs and pathways, we speculate that epigenetic regulators like DOT1L may have been similarly used to drive the evolution of novel immune differentiation pathways. This evidence concerns the gene DOT1L and leukemia.